NATCO PHARMA LTD.

The investor presentation from NATCO Pharma Limited, dated August 19, 2026, provided a comprehensive overview of the company's operations, financial performance, and strategic initiatives. The presentation reported global revenues of INR 43,759 million for FY26, with a focus on niche and complex molecules in the pharmaceutical sector. Management highlighted the company's strong manufacturing capabilities, with multiple USFDA-approved facilities and a robust R&D team comprising over 500 scientists. Key business segments included export formulations, domestic formulations, active pharmaceutical ingredients (API), and crop health sciences, with significant growth in each area. The document also detailed recent product launches and strategic investments in cell and gene therapy. Financial metrics showed a consolidated profit after tax of INR 14,185 million for FY26, reflecting a strong operational performance. The presentation concluded with insights into future strategies aimed at expanding market presence and enhancing product offerings.

Management emphasized strong growth and strategic initiatives across various business segments.